BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng W, Wang Y, Hu H, Wang Q, Bergmann SM, Wang Y, Li B, Lv Y, Li H, Yin J, Li Y. Cell Culture-Derived Tilapia Lake Virus-Inactivated Vaccine Containing Montanide Adjuvant Provides High Protection against Viral Challenge for Tilapia. Vaccines (Basel) 2021;9:86. [PMID: 33503930 DOI: 10.3390/vaccines9020086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng W, Wang Y, Chen X, Wang Q, Bergmann SM, Yang Y, Wang Y, Li B, Lv Y, Li H, Lan W. Potency and efficacy of VP20-based vaccine against tilapia lake virus using different prime-boost vaccination regimens in tilapia. Aquaculture 2021;539:736654. [DOI: 10.1016/j.aquaculture.2021.736654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Mai TT, Kayansamruaj P, Taengphu S, Senapin S, Costa JZ, Del-Pozo J, Thompson KD, Rodkhum C, Dong HT. Efficacy of heat-killed and formalin-killed vaccines against Tilapia tilapinevirus in juvenile Nile tilapia (Oreochromis niloticus). J Fish Dis 2021;44:2097-109. [PMID: 34477227 DOI: 10.1111/jfd.13523] [Reference Citation Analysis]
3 Falco A, Bello-Perez M, Díaz-Puertas R, Mold M, Adamek M. Update on the Inactivation Procedures for the Vaccine Development Prospects of a New Highly Virulent RGNNV Isolate. Vaccines (Basel) 2021;9:1441. [PMID: 34960187 DOI: 10.3390/vaccines9121441] [Reference Citation Analysis]
4 Lv Y, Wang Y, Wang Q, Li Y, Yin J, Yang G, Shi C, Li B, Wang Y, Bergmann SM, Zeng W. Development and characterization of a new cell line from brain tissues of the rare minnow ( Gobiocypris rarus ). Aquaculture Research. [DOI: 10.1111/are.15702] [Reference Citation Analysis]
5 Chamtim P, Suwan E, Dong HT, Sirisuay S, Areechon N, Wangkahart E, Hirono I, Mavichak R, Unajak S. Combining segments 9 and 10 in DNA and recombinant protein vaccines conferred superior protection against tilapia lake virus in hybrid red tilapia (oreochromis sp.) compared to single segment vaccines. Front Immunol 2022;13:935480. [DOI: 10.3389/fimmu.2022.935480] [Reference Citation Analysis]
6 Mai TT, Kayansamruaj P, Soontara C, Kerddee P, Nguyen D, Senapin S, Costa JZ, del-Pozo J, Thompson KD, Rodkhum C, Dong HT. Immunization of Nile Tilapia (Oreochromis niloticus) Broodstock with Tilapia Lake Virus (TiLV) Inactivated Vaccines Elicits Protective Antibody and Passive Maternal Antibody Transfer. Vaccines 2022;10:167. [DOI: 10.3390/vaccines10020167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Novoa B, Pereiro P. Editorial of Special Issue “The 2nd Edition: Vaccines for Aquaculture”. Vaccines 2022;10:1242. [DOI: 10.3390/vaccines10081242] [Reference Citation Analysis]
8 Yang YF, Yamkasem J, Surachetpong W, Lin YJ, You SH, Lu TH, Chen CY, Wang WM, Liao CM. Assessing the effect of probiotics on tilapia lake virus-infected tilapia: Transmission and immune response. J Fish Dis 2022. [PMID: 35514291 DOI: 10.1111/jfd.13635] [Reference Citation Analysis]
9 Mondal H, Chandrasekaran N, Mukherjee A, Thomas J. Viral infections in cultured fish and shrimps: current status and treatment methods. Aquacult Int. [DOI: 10.1007/s10499-021-00795-2] [Reference Citation Analysis]
10 Lertwanakarn T, Trongwongsa P, Yingsakmongkol S, Khemthong M, Tattiyapong P, Surachetpong W. Antiviral Activity of Ribavirin against Tilapia tilapinevirus in Fish Cells. Pathogens 2021;10:1616. [PMID: 34959571 DOI: 10.3390/pathogens10121616] [Reference Citation Analysis]